F-SMBT-1 : A Selective and Reversible Positron-Emission Tomography Tracer for Monoamine Oxidase-B Imaging Running title : 18 F-SMBT-1 , a novel MAO-B PET tracer

[1]  K. Ishii,et al.  18F-THK5351 PET Can Identify Astrogliosis in Multiple Sclerosis Plaques. , 2020, Clinical nuclear medicine.

[2]  K. Bötzel,et al.  PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes , 2019, Front. Aging Neurosci..

[3]  Jae Seung Kim,et al.  THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report , 2019, BMC Neurology.

[4]  C. Halldin,et al.  Synthesis and preclinical evaluation of [18F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B. , 2019, Bioorganic & medicinal chemistry letters.

[5]  K. Ishii,et al.  Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case. , 2019, Clinical nuclear medicine.

[6]  Allen F. Brooks,et al.  Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. , 2019, ACS chemical neuroscience.

[7]  Stephen F. Carter,et al.  Astrocyte Biomarkers in Alzheimer's Disease. , 2019, Trends in molecular medicine.

[8]  H. Arai,et al.  [18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review , 2018, BMC Neurology.

[9]  T. Yen,et al.  Visualization of ischemic stroke-related changes on 18F-THK-5351 positron emission tomography , 2018, EJNMMI Research.

[10]  S. Furumoto,et al.  Practical microscale one-pot radiosynthesis of 18 F-labeled probes. , 2018, Journal of labelled compounds & radiopharmaceuticals.

[11]  M. Kameyama,et al.  Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction. , 2017, Clinical nuclear medicine.

[12]  D. Na,et al.  [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia , 2017, Alzheimer disease and associated disorders.

[13]  H. Arai,et al.  Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease , 2017, The Journal of Nuclear Medicine.

[14]  S. Kish,et al.  Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders , 2017, Brain : a journal of neurology.

[15]  A. Takeda,et al.  In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET , 2016, Neurology.

[16]  H. Arai,et al.  Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351 , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  N. Okamura,et al.  Structure–Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[18]  N. Okamura,et al.  Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer , 2016, Molecular Imaging and Biology.

[19]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[20]  P. Fazio,et al.  In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl , 2016, The Journal of Nuclear Medicine.

[21]  N. Volkow,et al.  Monoamine oxidase: radiotracer chemistry and human studies. , 2015, Journal of labelled compounds & radiopharmaceuticals.

[22]  Alan A. Wilson,et al.  Kinetic Modeling of the Monoamine Oxidase B Radioligand [11C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  C. Halldin,et al.  Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). , 2013, Bioorganic & medicinal chemistry.

[24]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[25]  H. Arai,et al.  Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans , 2013, EJNMMI Research.

[26]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  C. Halldin,et al.  Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). , 2012, Bioorganic & medicinal chemistry.

[28]  B. Gulyás,et al.  Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography , 2011, Neurochemistry International.

[29]  O. Curet,et al.  [11C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: Preclinical characterisation in nonhuman primate , 2010, Synapse.

[30]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[31]  N. Volkow,et al.  Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  V. Chan‐Palay,et al.  Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography , 1994, Neuroscience.

[33]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  C. Halldin,et al.  Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl , 1991, Brain Research.

[35]  C. D. Arnett,et al.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.

[36]  K. Ishiwata,et al.  Biodistribution of a positron-emitting suicide inactivator of monoamine oxidase, carbon-11 pargyline, in mice and a rabbit. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  A. Buck,et al.  In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B. , 1998, Nuclear medicine and biology.